ArticleFrontiers in medicine2026
Exploring the celecoxib-cervical cancer relationship using
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To clarify the potential anticancer role of celecoxib and its immune-related mechanisms. Material and method: We confirmed the antitumor effects of celecoxib using Cell Counting Kit-8, wound-healing, colony-formation, and transwell assays. Network pharmacology and enrichment analyses were performed to identify pathways linking celecoxib to cervical cancer. Based on these results, two-sample and two-step Mendelian randomization (MR) analyses using blood expression quantitative trait loci instruments were conducted to evaluate the causal effect of NEU1 inhibition-the key celecoxib target-on cervical cancer risk and to assess immune cell mediation. Results: Celecoxib significantly inhibited cervical cancer cell proliferation, migration, colony formation, and invasion. Network pharmacology and enrichment analyses consistently highlighted T-cell-related immune pathways. MR revealed that genetically proxied NEU1 inhibition reduced cervical cancer risk ( Conclusion: By integrating genetic causal inference,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.